Design Therapeutics: Not A Complete Washout Despite Setback
Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results ...
Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
Jupiter is actively exploring additional strategic partnerships to expand JOTROL’s application across other neuroinflammatory and metabolic disorders, including Alzheimer’s disease and longevity ...
Jupiter Neurosciences, Inc.: Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based ...
Jupiter Neurosciences partners with Zina for Parkinson's trial
JUPITER, FL - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company with a market ...
Equus Magazine11h
Wisconsin Mare Tests Positive for EHV-1
On January 16, a 6-year-old Belgian mare in Clark County, Wisconsin, tested positive for equine herpesvirus-1 (EHV-1) after ...